Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1a/1b, First-in-Human, Open-Label, Multi-Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LB-LR1109, When Administered Alone for the Treatment of Advanced or Metastatic Solid Tumors, and in Combination With Atezolizumab for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06332755
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:56.583910+00:00
Published At
2025-11-24T00:00:00+00:00
Record Updated At
2025-11-24
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Non-small Cell Lung Cancer(NSCLC)", "Head and Neck Squamous Cell Carcinoma(HNSCC)", "Renal Cell Carcinoma(RCC)", "Urothelial Carcinoma", "Malignant Melanoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-11-24"
protocolSection.identificationModule.nctId
"NCT06332755"
protocolSection.identificationModule.officialTitle
"A Phase 1a/1b, First-in-Human, Open-Label, Multi-Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LB-LR1109, When Administered Alone for the Treatment of Advanced or Metastatic Solid Tumors, and in Combination With Atezolizumab for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Non-small Cell Lung Cancer(NSCLC) (protocolSection.conditionsModule.conditions)
  • Head and Neck Squamous Cell Carcinoma(HNSCC) (protocolSection.conditionsModule.conditions)
  • Renal Cell Carcinoma(RCC) (protocolSection.conditionsModule.conditions)
  • Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Malignant Melanoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.